Table 4.

Annual risk of de novo cardiac event according to the chelation regime

	DFO	DFP	Comb
Year	Events/exposed1, % risk (95% C.I.)	Events/exposed, % risk (95% C.I.)	Events/exposed, % risk (95% C.I.)
1999	16/338 4.7 (2.7–7.6)	0/0 (n.a.)	0/0 (n.a.)
2000	8/316 2.5 (1.1–4.9)	0/2 0 (0–84.1)2	0/4 0 (0–60.2)2
2001	13/282 4.6 (2.5–7.7)	0/16 0 (0–20.6)2	0/17 0 (0–19.5)2
2002	7/246 2.8 (1.2–5.4)	0/18 0 (0–18.5)2	0/40 0 (0–8.8)2
2003	5/189 2.6 (0.9–6.1)	1/42 2.4 (0.06–12.6)	0/63 0 (0–5.7)2
2004	6/147 4.1 (1.5–8.7)	0/63 0 (0–5.7)2	0/69 0 (0–5.2)2
2005	1/111 0.9 (0.02–4.9)	1/58 1.7 (0.04–9.2)	0/92 0 (0–3.9)2
2006	2/69 2.9 (0.4–10)	0/50 0 (0–7.1)2	1/115 0.9 (0.02–4.7)
2007	1/43 2.3 (0.06–12.3)	0/35 0 (0–10)2	0/99 0 (0–3.6)2
2008	0/33 0 (0–10.6)2	0/43 0 (0–8.2)2	0/98 0 (0–3.6)2

DFO, desferrioxamine; DFP, deferiprone.

¹Number of persons at risk for de novo cardiac event in each treatment group.

²One-sided, 97.5% confidence interval.